Diffuse hemispheric glioma, H3 G34-mutant
Clinical trials for Diffuse hemispheric glioma, H3 G34-mutant explained in plain language.
Never miss a new study
Get alerted when new Diffuse hemispheric glioma, H3 G34-mutant trials appear
Sign up with your email to follow new studies for Diffuse hemispheric glioma, H3 G34-mutant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a targeted antibody take on glioblastoma?
Disease control OngoingThis phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental vaccine trains immune system to attack deadly brain cancer
Disease control OngoingThis early-phase trial tests a personalized vaccine made from a patient's own white blood cells to treat a rare and aggressive brain tumor called H3 G34-mutant diffuse hemispheric glioma. The vaccine is designed to help the immune system recognize and kill tumor cells. Six adults…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC